StockData
Bicycle Therapeutics PLC logo

Bicycle Therapeutics PLC (BCYC) stock

BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.11−0.09 (-2.81%)

Close on Nov 18, 2026Market cap $217.99MP/E –Yield 0.00%

Bicycle Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Bicycle Therapeutics's operating income for the twelve months ending Sep 30, 2026 was -$158.23M. For fiscal 2025 it was -$247.07M. The highest annual figure on record is -$16.21M in fiscal 2017.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$247.07M–
FY2024Dec 31, 2024-$209.87M–
FY2023Dec 31, 2023-$189.95M–
FY2022Dec 31, 2022-$116.65M–
FY2021Dec 31, 2021-$65.62M–
FY2020Dec 31, 2020-$51.96M–
FY2019Dec 31, 2019-$26.30M–
FY2018Dec 31, 2018-$21.75M–
FY2017Dec 31, 2017-$16.21M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$13.48M–
Q2 FY2026Jun 30, 2026-$54.56M–
Q1 FY2026Mar 31, 2026-$65.48M–
Q4 FY2025Dec 31, 2025-$24.71M–
Q3 FY2025Sep 30, 2025-$65.55M–
Q2 FY2025Jun 30, 2025-$86.60M–
Q1 FY2025Mar 31, 2025-$70.20M–
Q4 FY2024Dec 31, 2024-$67.66M–
Q3 FY2024Sep 30, 2024-$63.85M–
Q2 FY2024Jun 30, 2024-$46.65M–
Q1 FY2024Mar 31, 2024-$31.72M–
Q4 FY2023Dec 31, 2023-$54.24M–
Q3 FY2023Sep 30, 2023-$50.80M–
Q2 FY2023Jun 30, 2023-$43.11M–
Q1 FY2023Mar 31, 2023-$41.80M–
Q4 FY2022Dec 31, 2022-$32.21M–
Q3 FY2022Sep 30, 2022-$29.76M–
Q2 FY2022Jun 30, 2022-$27.30M–
Q1 FY2022Mar 31, 2022-$27.38M–
Q4 FY2021Dec 31, 2021-$18.02M–
Q3 FY2021Sep 30, 2021-$14.29M–
Q2 FY2021Jun 30, 2021-$17.28M–
Q1 FY2021Mar 31, 2021-$16.02M–
Q4 FY2020Dec 31, 2020-$17.06M–
Q3 FY2020Sep 30, 2020-$10.68M–
Q2 FY2020Jun 30, 2020-$12.58M–
Q1 FY2020Mar 31, 2020-$11.64M–
Q4 FY2019Dec 31, 2019-$4.76M–
Q3 FY2019Sep 30, 2019-$10.25M–
Q2 FY2019Jun 30, 2019-$7.99M–
Q1 FY2019Mar 31, 2019-$3.29M–
Q4 FY2018Dec 31, 2018-$7.54M–
Q3 FY2018Sep 30, 2018-$6.36M–
Q2 FY2018Jun 30, 2018-$4.96M–

More Bicycle Therapeutics figures

See a number that looks wrong?